This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

DOI 10.1101/2025.04.10.647635

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedFeb 1, 2025

Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition.

Florencia P. Madorsky Rowdo, Rachel N. Martini, Sarah E. Ackermann…·M. Laura Martín

The paper uses CRISPR-Cas9 screens in breast cancer organoids from African ancestry patients to identify essential kinases and show synergy between EGFR and FGFR1 inhibitors.

23 citationstop 3%

humanorganoid / primary culture

𝕏 PostBluesky

Cancer BiologybioRxivJun 22, 2023

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment

Florencia P. Madorsky Rowdo, Gu Xiao, Galina F. Khramtsova…·Jill Bargonetti

This study shows that tumor organoids with mutant p53 are more sensitive to the combination of PARP inhibitor and temozolomide than those with wild-type p53.

DOI 10.1016/j.canlet.2024.216608

humanorganoid / primary culture

𝕏 PostBluesky

Developmental BiologyFrontiers in Cell and Developmental BiologyPeer-reviewedAug 26, 2021

A new pipeline to automatically segment and semi-automatically measure bone length on 3D models obtained by Computed Tomography

Santiago Beltran Diaz, Xinli Qu, Michael Doube…·Alberto Roselló‐Díez

The paper presents a semi-automated pipeline for fast and non-destructive measurement of bone length from micro-CT images of mouse developmental samples.

5 citations

mouseimaging

𝕏 PostBluesky